Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 143-page report is available in PDF from $2000.

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015’, provides an overview of the Retinitis Pigmentosa (Retinitis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Retinitis Pigmentosa (Retinitis) Overview 11
Therapeutics Development 12
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Overview 12
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Comparative Analysis 13
Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies 14
Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes 17
Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Retinitis Pigmentosa (Retinitis) - Products under Development by Companies 22
Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes 24
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 25
Acucela Inc. 25
Amarantus Bioscience Holdings, Inc. 26
Applied Genetic Technologies Corporation 27
Asklepios BioPharmaceutical, Inc. 28
BioDiem Ltd 29
Caladrius Biosciences, Inc. 30
DNAVEC Corporation 31
Dompe Farmaceutici S.p.A. 32
Genable Technologies Limited 33
GenSight Biologics SA 34
Grupo Ferrer Internacional, S.A. 35
International Stem Cell Corporation 36
Isis Pharmaceuticals, Inc. 37
Mimetogen Pharmaceuticals Inc. 38
Neurotech Pharmaceuticals, Inc. 39
Ocata Therapeutics, Inc. 40
Orphagen Pharmaceuticals, Inc. 41
QLT Inc. 42
R-Tech Ueno, Ltd. 43
ReNeuron Group Plc 44
Sanofi 45
Shire Plc 46
Spark Therapeutics, Inc. 47
Sun Pharma Advanced Research Company Ltd. 48
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Target 50
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
AMRS-001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BDM-E - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BNP-RP - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CB-11 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ECL-1 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
emixustat hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
FIB-111 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Gene Therapy for Ocular Diseases - Drug Profile 70
Product Description 70

For more information open Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015.


Original Article: Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015


More From BioPortfolio on "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...